Virological and serological tools to optimize the management of patients with chronic hepatitis B

Liver International

Volumn 36, Issue , 2016, Pages 78-84

  Martinot Peignoux, Michelle ^a,b   Marcellin, Patrick ^a,b,c  

^a CENTRE DE RECHERCHE SUR L INFLAMMATION   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c BEAUJON HOSPITAL   (France)

Author keywords

Analogues; Genotype; HBV; PEG IFN; Personalized medicine; Prediction; Prognosis

Indexed keywords

CIRCULAR DNA; HEPATITIS B SURFACE ANTIGEN; ALPHA INTERFERON; ANTIVIRUS AGENT; BIOLOGICAL MARKER; VIRUS DNA;

CHRONIC HEPATITIS B; CLINICAL PRACTICE; DISEASE COURSE; FOLLOW UP; HEPATITIS B VIRUS GENOTYPE A; HUMAN; MEDICAL INFORMATION; META ANALYSIS; PATIENT MONITORING; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; REVIEW; SEROCONVERSION; SEROLOGY; TREATMENT RESPONSE; BLOOD; DISEASE MANAGEMENT; GENETICS; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; PROGNOSIS;

ANTIVIRAL AGENTS; BIOMARKERS; DISEASE MANAGEMENT; DNA, CIRCULAR; DNA, VIRAL; GENOTYPE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; PROGNOSIS;

EID: 84952815555     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12998     Document Type: Review

References (52)

1. Kim BK, Revill PA, Ahn SH. HVB genotypes; relevance to natural history, pathogenesis and treatment of chronic hepatitis B. Antivir Ther 2011; 16: 1169-86.
2. Kao JH. Hepatitis B viral genome: clinical relevance and molecular characteristics. J Gastroenterol Hepatol 2002; 17: 643-50.
3. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000; 118: 554-89.
4. Martinot-Peignoux M, Carvalho RJ, Lapalus M, et al. Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naive, e-antigen-positive patients. J Hepatol 2013; 58: 1089-95.
5. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and response to interferon therapy. J Hepatol 2000; 33: 998-1002.
6. Wiegand J, Hasenclever D, Tillmann H. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence. Antivir Ther 2008; 13: 211-20.
7. Hoofnagle JH, Doo E, Liang J, Fleisher R, Lok ASF. Management of hepatitis B; summary of a clinical research workshop. Hepatology 2007; 45: 1056-75.
8. Gerlich WH. Medical virology of hepatitis B: how it began and where are we now. Virol J 2013; 10: 239-64.
9. Saldanha J, Gerlich W, Lelie N, et al.; WHO collaborative study group. An international collaborative study to establish a world Health organization standard for hepatitis B virus DNA nucleic acide amplification. Vox Sang 2001; 80: 63-71.
10. Janssen HLA, Kerhof-Los CJ, Heijtink RA, Schalm SW. Measurement of HBsAg to monitor hepatitis B viral replication in patients on α-interferon therapy. Antivir Res 1994; 23: 251-7.
11. Chan HL, Thompson A, Martinot-Peignoux Piratvisuth T, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011-A core group report. J Hepatol 2011; 55: 1121-31.
12. Martinot-Peignoux M, Asselah T, Marcellin P. HBsAg quantification to predict natural history and treatment outcome in chronic hepatitis B patients. Clin Liver Dis 2013; 17: 399-412.
13. Wursthorn K, Jaroszewicz J, Zacher BJ, et al. Correlation between the Elecsys HBsAg II assay and the architect assay for quantification of hepatitis B surface antigen (HBsAg) in serum. J Clin Virol 2011; 50: 292-6.
14. Tseng TC, Liu CJ, Yang HC, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012; 142: 1140-9.
15. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2012; 50: 227-42.
16. Flink HJ, van Zonneveld M, Hansen BE, et al.; HBV99-01study group. Treatment with Peg-interferon alpha-2b for HBe-Ag positive chronic hepatitis B: HBs loss is associated with genotype. Am J Gastroenterol 2006; 101: 297-303.
17. Erhardt A, Blondin D, Hauck K, et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive than genotype D. Gut 2005; 54: 1009-13.
18. Bonino F, Marcellin P, Lau GKK, et al. Predicting response to peginterferon alfa-2a, lamivudine and the two combined for HBeAg negative chronic hepatitis B. Gut 2007; 56: 699-705.
19. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95.
20. Papatheodoridis GV, Maneis EK, Manolakopoulos S, et al. Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection? Hepatology 2008; 48: 1451-9.
21. Buster EHC, Hansen BE, Lau GKK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterfron-alpha. Gastroenterology 2009; 137: 2002-9.
22. Chan HL, Wong VW, Chim AM, et al. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Aliment Pharmacol Ther 2010; 32: 1323-315.
23. Tangkijvanich P, Komolmit P, Mahachai V, et al. Low pretreatment serum HBsAg level and viral mutations as predictors of response to Peginterferon alfa-2b therapy in chronic hepatitis B. J Clin Virol 2009; 46: 117-23.
24. Chen GY, Zhu MF, Zheng DL, et al. Baseline HBsAg predicts response to pegylated interferon alfa 2b in HBeAg positive chronic hepatitis B patients. World J Gastroenterol 2014; 20: 8195-200.
25. Piratvisuth T, Marcellin P, Popescu M, et al. Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen positive patients. Hepatol Int 2013; 7: 429-36.
26. Martinot-Peignoux M, Asselah T, Marcellin P. HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients. Liver Int 2015; 35(Suppl): 82-90.
27. Moucari R, Martinot-Peignoux M, Mackiewicz V, et al. Influence of genotype on hepatitis B surafce antigen in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha-2a. Antivir Ther 2009; 14: 1183-8.
28. Sonneveld MJ, Rijckborst V, Cakaloglu Y, et al. Durable hepatitis surface antigen decline in hepatitis B e antigen positive chronic hepatitis B patients treated with pegylated interferon-a2b: relation to response and HBV genotype. Antivir Ther 2012; 17: 9-17.
29. Brunetto MR, Marcellin P, Cherubin B, et al. Response to peginterferon alfa-2a(40KD) in HBeAg-negative CHB: on treatment kinetics of HBsAg serum levels vary by HBV genotype. J Hepatol 2013; 53: 1153-9.
30. Hadziyannis SJ. Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients. Expert Opin Investig Drugs 2007; 16: 777-86.
31. Rijckborst V, Hansen BE, Cakaloglu Y, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010; 52: 454-61.
32. Marcellin P, Bonino F, Yurdayin C, et al. Hepatitis B surface antigen levels: association with 5-years response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. Hepatol Int 2013; 1: 88-94.
33. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 1151-7.
34. Brunetto MR, Moriconi F, Bononi F, et al. Hepatitis B virus surface antigen levels: a guide to sutained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 1141-50.
35. Sonneveld MJ, Hansen BE, Piratvisuth T, et al. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis surface antigen levels. Hepatology 2013; 58: 872-80.
36. Rijckborst V, Hansen BE, Ferenci P, et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alpha-2a. J Hepatol 2012; 6: 1006-11.
37. Moucari R, Korevaar A, Lada O, et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol 2009; 50: 1084-92.
38. Wursthorn K, Jung M, Riva A, et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 2010; 52: 1611-20.
39. Gish R, Chang TT, Lai CL, et al. Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naive patients treated with entecavir. Antivir Ther 2013; 18: 691-8.
40. Marcellin P, Buti M, Krastev Z, et al. Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate. J Hepatol 2014; 61: 1228-37.
41. Zeuzem S, Gane E, Liaw YF, et al. Baseline characteristics and early on treatment response predict the outcome of 2 years of telbuvidine treatment of chronic hepatitis B. J Hepatol 2009; 51: 11-20.
42. Seto WK, Wong DKH, Fung J, et al. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology 2013; 58: 923-31.
43. Marcellin M, Heathcote EJ, Buti M, et al. Tenofovir Disiproxil Fumarate versus Adefovir Dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-55.
44. Heathcote EJ, Marcellin M, Buti M, et al. Three years efficacy and safety of Tenofovir Disiproxil Fumarate treatment for chronic hepatitis B. Gastroenterology 2011; 140: 132-43.
45. Reijnders JG, Rijckborst V, Sonneveld MJ, et al. Kinetics of hepatits B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol 2011; 54: 449-54.
46. Lee JM, Ahn SH, Kim HS, et al. Quantitative hepatitis B surface antigen and hepatitis B e atigen titers in prediction of treatment response to entecavir. Hepatology 2010; 53: 1486-93.
47. Lee MH, Lee DM, Kim SS, Cheong JY, Cho SW. Correlation of serum hepatitis B srface antigen level with response to entecavir in naive patients with chronic hepatitis B. J Med Virol 2011; 83: 1178-86.
48. Zoulim F, Carosi G, Greenbloom S, et al. Quantification of HBsAg in nucleos(t)ides-naive patients treated for chronic hepatitis B with entecavir or entecavir plus tenofovir in the BE-LOW study. J Hepatol 2015; 62: 56-63.
49. Liang Y, Jiang J, Su M, et al. Predictors of relapse in chronic hepatitis B after discontinuation of antiviral therapy. Aliment Pharmacol Ther 2011; 34: 344-52.
50. Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B; a 2012 update. Hepatol Int 2012; 6: 531-61.
51. Seto WK, Hui AJ, Wang VWS, et al. Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronis hepatitis B; a multicenter prospective study. Gut 2015; 64: 667-72.
52. Chang ML, Liaw YF, Hadziyannis SL. Systemetic review; cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen negative chronis hepatitis B. Aliment Pharmacol Ther 2015; 42: 243-57.